Sign in
Taking peoplePhase 2

Levosimendan in Cardiac Arrest: A Randomized Double-blinded Clinical Phase II Trial (LeICA)

Key facts

Who runs it
Karolinska University Hospital
Where
Sweden1 site in 1 countryChoose a country to see its sites
Status
Recruiting
Phase
Phase 2
People taking part
40 people, planned
Started
14 Apr 2026
Expected to end
30 Jun 2027
Type of study
Interventional
Record updated
11 June 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (12)Hide the full registry criteria

Who can take part

  • Witnessed OHCA
  • Prompt start of CPR (within 2 minutes)
  • First recorded rhythm VF or pVT, or PEA in case of suspected pulmonary embolism (as determined by the attending physician)
  • Refractory cardiac arrest, i.e. sustained beyond third rhythm check
  • Intravenous access
  • Age 18-75 years

Who cannot take part

  • Traumatic cause of cardiac arrest
  • Time to administration of study drug >30 min after onset of cardiac arrest
  • Known pre-existing severe neurological or systemic disease (e.g. severe dementia, current advanced malignancy, advanced cardiac or pulmonary disease, terminal chronic kidney disease on dialysis)
  • First recorded rhythm asystole
  • Known or apparent pregnancy
  • Known pre-existing (i.e. current) DNACPR decision

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Cardiac arrest

This trial is currently available in Sweden.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To investigate if a single dose of levosimendan given during cardiopulmonary resuscitation (CPR) for out-of-hospital cardiac arrest (OHCA) increases 30-day survival compared to placebo.

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Criteria questions
Built from 2024-517279-20-02, who can take part
Record updated
11 June 2025